CSL Earnings Slashed Amidst Vaccination Decline
CSL has significantly revised its earnings and revenue forecasts due to a decline in US vaccination rates.
This announcement coincides with the company's decision to shelve plans for the demerger of its Seqirus vaccines business.
Furthermore, CSL faces a potential board spill following a second consecutive year of shareholder rejection of the company's remuneration report.
- 12 per cent drop in US vaccination rates anticipated during the upcoming northern hemisphere winter.
The announcement was made ahead of CSL's annual general meeting.
Author's summary: CSL revises earnings forecast due to declining US vaccination rates.